RT Journal Article
SR Electronic
T1 Seronegative spondyloarthropathies: to lump or split?
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP ii9
OP ii13
DO 10.1136/ard.2004.033654
VO 64
IS suppl 2
A1 Nash, P
A1 Mease, P J
A1 Braun, J
A1 van der Heijde, D
YR 2005
UL http://ard.bmj.com/content/64/suppl_2/ii9.abstract
AB The advent of novel biological therapies for the treatment of rheumatic disease has renewed interest in the seronegative spondyloarthropathies (SpAs). International efforts are redefining disease classification and measures of disease activity, outcome, metrology, and imaging. However, opinion is divided between those who propose that the SpA group represents the same disease with variable expression (the “lumpers”) and those who consider these to be separate diseases with shared clinical features (the “splitters”). This review presents the evidence for both approaches.